Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study

LAUREL Study Group

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study'. Together they form a unique fingerprint.

Medicine & Life Sciences